Release of therapeutic agents in a vessel or tissue

• US 20040062797A1
• Filed: 09/30/2003
• Published: 04/01/2004
• Est. Priority Date: 05/10/2000
• Status: Abandoned Application

• Current Assignee: Trimedyne Incorporated (InnovaQuartz, LLC)
• Original Assignee: Trimedyne Incorporated (InnovaQuartz, LLC)
• Inventors: Loeb, Marvin P.
• Application Number:
  US10/675,844
• Publication Number:
  US 20040062797A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 9/127 Liposomes

Abstract

Particles larger than 7 microns in diameter and containing a therapeutic material are described. Such particles are sufficiently large to lodge in tissue or a blood vessel and can be made to rapidly degrade therein before creating infarcts. Rapid degradation of liposomes containing a therapeutic agent can be achieved by either preparing the liposome in a high salt solution or incorporating in the liposome a component which is stable at or below room temperature, but which becomes unstable at 35° C. or higher. Such particles are useful in delivering, for example, angiogenic growth factors or genes coding for angiogenic growth factors into the coronary arteries of the heart or the heart muscle, as well as other therapeutic agents into organs or tissues or blood vessels feeding the same to achieve a desired effect.

Claims

1. A physiologically compatible liposome containing at least one therapeutic agent;

said liposome comprising dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylcholine and cholesterol in a respective weight ration of about 7;

3;

5, having a diameter of at least about 7 microns but no more than about 300 microns, and a residence time in a body fluid of at least about one half-minute but less than about 3 minutes.

2. The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is hydrophilic.

3. The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is lipophilic.

4. The physiologically compatible particle in accordance with claim 1 wherein the liposome contains a hydrophilic therapeutic agent and a lipophilic therapeutic agent.

5. The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is a biologically active substance.

6. The physiologically compatible particle in accordance with claim 5 wherein the biologically active substance is a gene.

7. The physiologically compatible particle in accordance with claim 5 wherein the biologically active substance is a protein.

8. The physiologically compatible particle in accordance with claim 5 wherein the biologically active substance is an enzyme.

9. The physiologically compatible particle in accordance with claim 5 wherein the biologically active substance is a monoclonal antibody.

10. The physiologically compatible particle in accordance with claim 5 wherein the biologically active substance is a cytokine.

11. The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is a nutrient.

12. The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is a vitamin.

13. The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is a chemotherapeutic substance.

14. The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is an organic compound.

15. The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is an inorganic compound.

16. The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is bone marrow.

17. The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is a stem cell.

18. The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is fibroblast growth factor.

19. The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is vascular endothelial growth factor.

20. The physiologically compatible particle in accordance with claim 1 which is a microsphere.

21. A method for introducing a therapeutic agent into the vasculature of a patient which comprises injecting into a patient'"'"'s blood stream physiologically compatible liposomes containing at least one therapeutic agent, which particles have a diameter of at least about 7 microns but no more than about 300 microns;

said liposomes comprising dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylcholine and cholesterol in a respective weight ratio of about 7;

3;

5 and having a residence time in the patient'"'"'s blood stream of at least about one-half minute but less than about 3 minutes.

22. The method in accordance with claim 21 wherein the physiologically compatible discrete particles are microspheres.

23. The method in accordance with claim 21 wherein the therapeutic agent is hydrophilic.

24. The method in accordance with claim 21 wherein the therapeutic agent is lipophilic.

25. The method in accordance with claim 21 wherein the particles are liposomes that contain a hydrophilic therapeutic agent with a lipophilic therapeutic agent.

26. The method in accordance with claim 21 wherein the therapeutic agent is a biologically active substance.

27. The method in accordance with claim 26 wherein the biologically active substance is a gene.

28. The method in accordance with claim 26 wherein the biologically active substance is a protein.

29. The method in accordance with claim 26 wherein the biologically active substance is an enzyme.

30. The method in accordance with claim 26 wherein the biologically active substance is a monoclonal antibody.

31. The method in accordance with claim 26 wherein the biologically active substance is a cytokine.

32. The method in accordance with claim 21 wherein the therapeutic agent is a nutrient.

33. The method in accordance with claim 21 wherein the therapeutic agent is a vitamin.

34. The method in accordance with claim 21 wherein the therapeutic agent is a chemotherapeutic substance.

35. The method in accordance with claim 21 wherein the therapeutic agent is an organic compound.

36. The method in accordance with claim 21 wherein the therapeutic agent is an inorganic compound.

37. The method in accordance with claim 21 wherein the therapeutic agent is a stem cell.

38. The method in accordance with claim 21 wherein the therapeutic agent is bone marrow.

39. The method in accordance with claim 21 wherein the therapeutic agent is fibroblast growth factor.

40. The method in accordance with claim 21 wherein the therapeutic agent is vascular endothelial growth factor.